Table 3.
Effects of a direct switch to IND/GLY from baseline treatments on CAT, CCQ and rescue medication use (ITT population)
| LABA + ICS n = 269 | IND/GLY n = 811 | LABA or LAMAa n = 268 | IND/GLYa n = 811 | |
|---|---|---|---|---|
| Total CAT score, change from baseline at Week 12 | −0.4 (4.8) | −1.4 (5.4) | −0.9 (5.0) | −1.9 (5.3) |
| Patients who achieved MCID in total CAT score (≥2 units difference from baseline), n (%) | 89 (33.1%) | 311 (38.4%) | 112 (41.8%) | 351 (43.3%) |
| CAT responders (decrease ≥2 units; OR [95% CI]) | 1.44 (1.06 to 1.95) | 1.12 (0.83 to 1.50) | ||
| Total CCQ score, change from baseline at Week 12 | −0.1 (0.7) | −0.2 (0.8)* | −0.1 (0.8) | −0.3 (0.8)*** |
| Patients who achieved MCID in the total CCQ score (≥0.4 units difference from baseline), n (%) | 64 (23.8%) | 243 (30.0%) | 74 (27.6%) | 293 (36.1%) |
| CCQ responders (decrease ≥0.4 units; OR [95% CI]) | 1.53 (1.10 to 2.12) | 1.58 (1.16 to 2.17) | ||
| Number of puffs of rescue medication over 12 weeks | 1.6 (1.7) | 1.1 (1.4)**** | 1.4 (1.4) | 1.1 (1.3)*** |
| Percentage of days without rescue medication use over 12 weeks | 41.7 (42.9) | 49.9 (43.4)** | 38.8 (42.6) | 46.7 (42.6)** |
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001
aPatients had an mMRC score ≥ 2
Data are presented as mean (stadard deviation), unless otherwise stated
CAT, COPD assessment test; CCQ, clinical COPD questionnaire; CI, confidence interval; COPD, chronic obstructive pulmonary disease; IND/GLY, indacaterol/glycopyrronium; ITT, intention-to-treat; LABA + ICS, long-acting β2-agonist + inhaled corticosteroid; LAMA, long-acting muscarinic antagonist; MCID, minimal clinically important difference; mMRC, modified Medical Research Council; OR, odds ratio